SCHEMBL5880308

SCHEMBL5880308

CCOc1ccccc1C(=O)N/N=C/c1ccccc1OS(=O)(=O)c1ccc(C(F)(F)F)cc1

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.53
KDM4E B2RXH2 3/20 0.52
MAPK1 P28482 1/20 0.52
LMNA P02545 5/20 0.49
HTT P42858 4/20 0.49
MEN1 O00255 4/20 0.49
KMT2A Q03164 4/20 0.49
TDP1 Q9NUW8 2/20 0.49
POLB P06746 1/20 0.49
ALDH1A1 P00352 3/20 0.49
RAB9A P51151 1/20 0.49
NPC1 O15118 1/20 0.47
CYP1A2 P05177 1/20 0.46
CYP3A4 P08684 1/20 0.46
CYP2D6 P10635 1/20 0.46
CYP2C9 P11712 1/20 0.46
CYP2C19 P33261 1/20 0.46
ATM Q13315 1/20 0.45
CRHBP P24387 1/20 0.45
CRHR2 Q13324 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6372497 1.00 MAPT (0.53) MAPTKDM4EMAPK1LMNAHTT
SCHEMBL6379352 0.90 LMNA (0.57) MAPTKDM4EMAPK1LMNAHTT
SCHEMBL5879870 0.90 LMNA (0.57) MAPTKDM4EMAPK1LMNAHTT
SCHEMBL5880054 0.88 MAPT (0.54) MAPTKDM4EMAPK1LMNAHTT
SCHEMBL6374926 0.88 MAPT (0.54) MAPTKDM4EMAPK1LMNAHTT
SCHEMBL5879956 0.87 KMT2A (0.50) MAPTKDM4EMAPK1LMNAHTT
SCHEMBL5879953 0.87 KMT2A (0.50) MAPTKDM4EMAPK1LMNAHTT
SCHEMBL5880133 0.87 MAPT (0.50) MAPTKDM4EMAPK1LMNAHTT
SCHEMBL5880130 0.87 MAPT (0.50) MAPTKDM4EMAPK1LMNAHTT
SCHEMBL5879978 0.86 MAPT (0.51) MAPTKDM4EMAPK1LMNAHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7026339-B2 Inhibitors of HCV NS5B polymerase PFIZER INC. 2006-04-11 US disclosed
US-20050154056-A1 [(hetero)aryl or cycloalkylacetylhydrazono]methylbenzene derivatives, o-substituted with (hetero)aryl- or cycloalkyl- sulfonyloxy-, sulfonylamino-, S(O)0-2methyl-, or methoxy- groups, e.g., 3-chloro-2-((E)-{[(3-methoxyphenyl)acetyl]hydrazono}methyl)phenyl 4-(trifluoromethyl)benzenesulfonate PHARMACIA & UPJOHN COMPANY 2005-07-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050154056-A1 [(hetero)aryl or cycloalkylacetylhydrazono]methylbenzene derivatives, o-substituted with (hetero)aryl- or cycloalkyl- sulfonyloxy-, sulfonylamino-, S(O)0-2methyl-, or methoxy- groups, e.g., 3-chloro-2-((E)-{[(3-methoxyphenyl)acetyl]hydrazono}methyl)phenyl 4-(trifluoromethyl)benzenesulfonate ACACB, HCCS, HAVCR2 MAPT 4629/4885KDM4E 439/4885MAPK1 3992/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.